Obesity Pillars,
Journal Year:
2023,
Volume and Issue:
5, P. 100059 - 100059
Published: Feb. 21, 2023
Once
thought
to
be
primarily
a
result
of
lifestyle,
it
is
now
known
that
obesity
has
significant
genetic
components.
Dozens
genes
have
been
linked
obesity,
and
office-based
testing
for
obesity-associated
readily
available.
As
both
pharmacotherapy
become
more
accessible,
pharmacogenetic
personalization
becoming
reality.
In
this
case
report,
patient
with
PLXNA4
polymorphism
had
superior
weight
loss
response
phentermine/topiramate
therapy
than
previously
reported
in
the
literature.
Thus,
variants
may
provide
basis
patient's
cardiovascular
risk
factor
reduction.
Obesity Pillars,
Journal Year:
2025,
Volume and Issue:
unknown, P. 100172 - 100172
Published: March 1, 2025
This
collaboration
from
the
Obesity
Medicine
Association
(OMA)
and
American
College
of
Osteopathic
Family
Physicians
(ACOFP)
examines
obesity
management
a
primary
care
perspective.
joint
perspective
is
based
upon
scientific
evidence,
clinical
experience
authors,
peer
review
by
OMA
ACOFP
leadership.
The
goal
to
identify
answer
sentinel
questions
about
perspective,
utilizing
evidence-based
publications,
guided
expert
experience.
disease
that
contributes
both
biomechanical
complications
most
common
cardiometabolic
abnormalities
encountered
in
care.
Barriers
impede
optimal
patients
with
include
failure
recognize
as
disease,
lack
accurate
diagnosis,
insufficient
access
treatment
resources,
inadequate
training,
time,
adequate
reimbursement
adverse
impact
bias,
stigma,
discrimination.
physicians
are
often
first
line
healthcare
setting.
affords
early
intervention
opportunities
prevent
and/or
treat
overweight
obesity.
Patient
enhanced
when
clinicians
risks
benefits
anti-obesity
medications
bariatric
procedures,
well
long-term
follow-up.
Practical
tools
regarding
4
pillars
nutrition
therapy,
physical
activity,
behavior
modification,
medical
interventions
(anti-obesity
surgery)
may
assist
improve
health
lives
living
Obesity Pillars,
Journal Year:
2024,
Volume and Issue:
9, P. 100099 - 100099
Published: Jan. 8, 2024
A
fixed-dose
combination
of
phentermine
and
extended-release
topiramate
(PHEN/TPM
-
approved
for
weight
management)
has
demonstrated
in-clinic
reduction
blood
pressure
(BP).
Ambulatory
BP
monitoring
(ABPM)
may
be
a
better
predictor
cardiovascular
disease
risk
than
BP.
Glucagon-like
peptide
1
(GLP-1)
receptor
agonists
are
revolutionizing
obesity
and
type
2
diabetes
treatment,
delivering
remarkable
weight
loss
outcomes.
These
medications,
leveraging
the
effects
of
insulin-regulating
hormone
GLP-1
via
actions
on
peripheral
central
nervous
system
targets,
have
raised
hopes
with
their
bariatric
surgery-rivaling
results.
However,
questions
remain
about
long-term
safety
efficacy.
Drawing
from
our
expertise
in
medicine
psychiatry,
we
reflect
upon
experiences
clinical
use
these
medications
delve
into
nuanced
challenges
risks
they
pose,
particularly
for
those
prone
to
disordered
eating
or
diagnosed
rare
genetic
diseases
obesity.
We
contend
that
effectively
managing
within
this
‘danger
zone’
necessitates
(1)
proactive
screening
continuous
monitoring
eating;
(2)
vigilant
appetite-related
maladaptive
responses,
including
food
aversion
dehydration;
(3)
ongoing
assessment
broader
health
impacts.
A
multifaceted,
interdisciplinary
approach
melds
medical,
psychological,
dietary,
behavioral
strategies
is
crucial
deliver
tailored
thorough
care
each
patient.
Journal of Nutrition,
Journal Year:
2024,
Volume and Issue:
154(9), P. 2732 - 2742
Published: July 16, 2024
Current
guidelines
for
the
treatment
of
obesity
recommend
dietary
restriction
to
create
a
caloric
deficit,
and
reductions
16%
68%
have
been
achieved
in
adults
with
overweight
or
engaging
intentional
weight
loss
programs.
This
study
models
impact
simulated
reduction
on
nutrient
adequacy
among
U.S.
≥19
y
using
National
Health
Nutrition
Examination
Survey
data
(2015–2018).
Four
levels
(20%,
30%,
40%,
50%)
were
modeled
by
prorating
daily
calorie
intake
such
that
usual
intakes
14
nutrients
reduced
proportional
reduction.
The
percentages
below
estimated
average
requirement
(EAR)
above
adequate
(AI)
at
each
level
reduction,
without
supplement
use.
Differences
across
determined
nonoverlapping
confidence
intervals
means
(97.5th
percentile
used
approximate
P
<
0.05).
There
significant
differences
(P
0.05)
EAR
(above
AI)
between
sequential
most
analyzed
(protein,
vitamins
A,
B-6,
folate,
C,
calcium,
iron,
magnesium,
potassium,
zinc).
For
example,
after
30%
25%–40%
population
had
protein,
vitamin
zinc,
75%–91%
magnesium
(vs.
4%–18%
45%–56%,
respectively,
reduction).
With
inclusion
supplements,
all
(except
protein)
lower
than
those
food
alone.
Caloric
may
exacerbate
inadequacies
obesity.
Inclusion
nutrient-dense
foods,
fortified
specially
formulated
products,
and/or
supplements
should
be
considered
calorie-restricted
diets
long-term
loss.
Obesity Pillars,
Journal Year:
2023,
Volume and Issue:
5, P. 100059 - 100059
Published: Feb. 21, 2023
Once
thought
to
be
primarily
a
result
of
lifestyle,
it
is
now
known
that
obesity
has
significant
genetic
components.
Dozens
genes
have
been
linked
obesity,
and
office-based
testing
for
obesity-associated
readily
available.
As
both
pharmacotherapy
become
more
accessible,
pharmacogenetic
personalization
becoming
reality.
In
this
case
report,
patient
with
PLXNA4
polymorphism
had
superior
weight
loss
response
phentermine/topiramate
therapy
than
previously
reported
in
the
literature.
Thus,
variants
may
provide
basis
patient's
cardiovascular
risk
factor
reduction.
